HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of...
Buy at suggested Entry Price and cut loss if the price goes lower than the Stop Loss. Can take profit at suggested Target Price.
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from...
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of...
Overall: * Negative EPS * June 7th conference @ASCO will most likely lead to a double-top. * The "surge" is starting to end, if not has already ended. Share price should return to anywhere between $8-11, possibly even lower. * Medical breakthroughs, as a whole, when it comes to cancers, which this company focuses on, are slow, unlikely, and uncommon. And I...
We have classic up trend with more volume in the last 20 days. All signs of good news and push higher.
+++++++ HOT STOCK FOR FRIDAY +++++++++ Shares of Hookipa Pharma Inc. (HOOK) surged in after-hours trading Thursday after the company said the FDA approved an early stage trial of its treatment for human papilloma virus (HPV)-positive cancers. The stock rose $2.46, or 37% to $9.14 in after-hours action. The company said in a statement that it intends to start the...